[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Longhua Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100629719",false,"NCT07478328","Chaigui Longmu Ejiao Paste for Ischemic Heart Disease","A Randomized, Double-Blind Clinical Trial of Chaigui Longmu Ejiao Paste in the Treatment of Ischemic Heart Disease With Internal and External Controls","Inclusion Criteria:\n\n1. Age 18-75 years, both sexes eligible;\n2. Meets the diagnostic criteria for stable angina pectoris in ischemic heart disease (IHD), with stable condition for ≥4 weeks;\n3. Has received standard Western medical treatment (including but not limited to antiplatelet agents, lipid-modifying\u002Fstabilizing plaque therapy, β-blockers, etc.) for at least 4 weeks, with stable dosages;\n4. Meets the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria of \"thoracic yang deficiency with heart vessel stasis\" (or \"chest yang insufficiency with heart meridian blood stasis\"), with primary symptoms: chest oppression\u002Fpain, palpitations; at least 2 secondary symptoms: insomnia, aversion to cold, spontaneous sweating, irritability or restlessness; supported by tongue and pulse findings;\n5. Has signed the informed consent form and is willing to participate voluntarily in the study.\n\nExclusion Criteria:\n\n1. Acute coronary syndrome or patients requiring emergency revascularization;\n2. Use of traditional Chinese medicine (TCM) or Chinese patent medicines with therapeutic effects on ischemic heart disease within the past 2 weeks;\n3. Poorly controlled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg after treatment);\n4. Severe heart failure (NYHA functional class IV), uncontrolled malignant arrhythmias, cardiogenic shock; severe cerebrovascular diseases; active or recurrent digestive system ulcers or other diseases with bleeding risk; other severe digestive system diseases; complicated with malignant tumors, hematological disorders, or other severe or progressive systemic diseases; complicated with other mental disorders that render the patient unable or unwilling to cooperate;\n5. Severe hepatic or renal impairment (ALT\u002FAST \\> 3 × upper limit of normal, or creatinine \\> 1.5 × upper limit of normal);\n6. Known allergy to any component of the study formula;\n7. Women who are pregnant, lactating, or planning pregnancy;\n8. Patients who have participated in other clinical trials within the past 3 months;\n9. Patients deemed by the investigator to be unsuitable for participation in the clinical trial.","ALL","18 Years","75 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study explores whether Chaigui Longmu Ejiao Paste can reduce the average weekly number of angina attacks in patients with ischemic heart disease after 8 weeks of treatment, using Chaigui Longmu Paste without Ejiao as a parallel control and incorporating a synthesized external control.",[26],"Ischemic Heart Disease","NOT_YET_RECRUITING","2026-03-13",{"date":30,"type":31},"2026-03-17","ACTUAL",{"date":33,"type":20},"2026-03-08",{"date":35,"type":20},"2028-12-31",{"name":37,"class":38},"Longhua Hospital","OTHER",""]